Singhal Priya 4

What Happened

• Priya Singhal, Head of Development at Biogen (BIIB), was granted 10,560 restricted stock units (RSUs) on February 13, 2026. The award is reported as a derivative acquisition at an acquisition price of $0.00, meaning no cash was paid by the insider at grant.

Key Details

• Transaction date: 2026-02-13; Filing date: 2026-02-17 (no late-filing flag indicated).
• Security: 10,560 restricted stock units (derivative securities); acquisition price reported $0.00.
• Shares owned after the transaction: not specified in the filing.
• Footnote: The RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date (Feb 13, 2027).
• Transaction type: Award/Grant (code A); not a market purchase or sale.

Context

• This is a grant of equity compensation, not a purchase or sale; such awards are routine for executives and are compensation rather than an explicit buy/sell signal.
• The RSUs convert into common shares as they vest (per the footnote), so future reporting will show when vested shares are delivered or withheld for taxes.